Complix is a private biopharmaceutical company developing a diverse oncology pipeline of Cell Penetrating Alphabodies (CPABs) including several pre-clinical in-house programs and two partnered programs with Merck & Co. The Company’s CPAB pipeline addresses intracellular oncogenic targets, both cytosolic and intranuclear, that play an important role in cancer development and progression.
CPABs are biologicals designed to overcome the limitations of current drug formats that make many intracellular disease targets difficult to address. They achieve this by combining the benefits of antibodies, including high specificity and potency, with those of small molecules, such as cell penetration and high stability.
Each CPAB is a small alpha-helical protein that contains a well-defined binding domain. The rigid structure of a CPAB allows Complix scientists to predict how the CPAB will bind to its target, thereby ensuring a high probability of success. By modifying the amino acid sequence in the binding domain of the CPAB, Complix researchers can design CPABs against a broad diversity of disease targets with exquisite precision and potency. In particular, CPABs are highly suited to act on intractable targets that are promoting abnormal cell growth in cancer.
Pre-clinical proof of concept data demonstrate that CPABs engage specifically with these targets and cause a therapeutic effect in animal models.
Complix’s goal is to use its unique CPAB technology to develop transformative oncology biotherapeutics and deliver value for its stakeholders in a large therapeutic area with high unmet medical need.
Complix is led by an experienced management team with a track record of success in the biotech industry and is backed by a syndicate of experienced life sciences investors, led by Andera Partners (France) and Gimv (Belgium), through which it has raised over €27 million to date.